Special Issue

Modulation of Innate Immunity in Cancer Immunotherapy

Message from the Guest Editors

Immunotherapy holds a great hope as a therapeutic approach against cancer. It is well known that tumor-infiltrating macrophages are critical mediators of innate immune responses against tumors and can either oppose or support them because of their plasticity. Therefore, harnessing innate immune responses to trigger subsequent T cell-mediated immunogenic responses is becoming a prominent new strategy in cancer immunotherapy. Along these lines, the activation of innate immunoreceptors overcomes resistance to anti-PD-1 immunotherapy, and immunotherapies can be boosted by targeted reprogramming of macrophages.

Of note, certain stimuli can trigger trained immunity (TI) in macrophages, natural killer cells, and dendritic cells. Remarkably, TI has been proven to be efficient against cancer and to boost ICI-based therapies in mice. These data reinforce the relevance of innate immunity for durable anti-tumor responses.

This Special Issue aims to present the current knowledge about the role of innate immune cells in cancer immunotherapy, including cutting-edge new findings in this field.

Dr. Carlos del Fresno Sánchez

Guest Editors

Dr. Carlos Del Fresno Sánchez
Hospital la Paz Health Research Institute, La Paz University Hospital, 28029 Madrid, Spain
Dr. Eduardo Lopez-Collazo
Hospital la Paz Institute for Health Research (IdiPAZ), Madrid, Spain

Deadline for manuscript submissions

closed (30 April 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/78283

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).